LIPI Stock Overview
A pharmaceutical development company, engages in the development of drugs for the treatment of psoriasis, acne vulgaris, bacterial skin infections, and atopic dermatitis. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Lipidor AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.24 |
| 52 Week High | SEK 1.35 |
| 52 Week Low | SEK 0.04 |
| Beta | 0.56 |
| 1 Month Change | 79.26% |
| 3 Month Change | 91.30% |
| 1 Year Change | -49.90% |
| 3 Year Change | -97.12% |
| 5 Year Change | -98.61% |
| Change since IPO | -96.41% |
Recent News & Updates
Recent updates
We're Hopeful That Lipidor (STO:LIPI) Will Use Its Cash Wisely
Sep 04
Lipidor (STO:LIPI) Is In A Strong Position To Grow Its Business
Feb 24We Think Lipidor (STO:LIPI) Can Afford To Drive Business Growth
Sep 15Here's Why We're Not At All Concerned With Lipidor's (STO:LIPI) Cash Burn Situation
May 13Companies Like Lipidor (STO:LIPI) Are In A Position To Invest In Growth
Jan 29Need To Know: Lipidor AB (publ) (STO:LIPI) Insiders Have Been Selling Shares
Dec 07
Shareholder Returns
| LIPI | SE Pharmaceuticals | SE Market | |
|---|---|---|---|
| 7D | 28.7% | 2.4% | 1.9% |
| 1Y | -49.9% | -5.7% | 7.6% |
Return vs Industry: LIPI underperformed the Swedish Pharmaceuticals industry which returned -8.4% over the past year.
Return vs Market: LIPI underperformed the Swedish Market which returned 6.3% over the past year.
Price Volatility
| LIPI volatility | |
|---|---|
| LIPI Average Weekly Movement | 10.9% |
| Pharmaceuticals Industry Average Movement | 9.5% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in SE Market | 11.4% |
| 10% least volatile stocks in SE Market | 3.2% |
Stable Share Price: LIPI's share price has been volatile over the past 3 months compared to the Swedish market.
Volatility Over Time: LIPI's weekly volatility has decreased from 30% to 11% over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 5 | Ola Holmlund | lipidor.se |
Lipidor AB (publ), a pharmaceutical development company, engages in the development of drugs for the treatment of psoriasis, acne vulgaris, bacterial skin infections, and atopic dermatitis. The company develops AKP-01, which is in Phase III for the treatment of psoriasis; and preclinical stage products, such as AKP-02 for psoriasis, AKP-03 for bacterial skin diseases, and AKP-07 for atopic dermatitis. It offers active pharmaceutical ingredients used in products for various therapeutic applications, such as anti-psoriasic, antimicrobial, anti-inflammatory, antifungal, local anesthetics, non-steroidal anti-inflammatory, anti-acne, wound healing, anti-eczema, and anti-migraine.
Lipidor AB (publ) Fundamentals Summary
| LIPI fundamental statistics | |
|---|---|
| Market cap | SEK 196.84m |
| Earnings (TTM) | -SEK 13.53m |
| Revenue (TTM) | SEK 93.00k |
2,117x
P/S Ratio-14.6x
P/E RatioIs LIPI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LIPI income statement (TTM) | |
|---|---|
| Revenue | SEK 93.00k |
| Cost of Revenue | SEK 9.26m |
| Gross Profit | -SEK 9.17m |
| Other Expenses | SEK 4.36m |
| Earnings | -SEK 13.53m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Feb 28, 2025
| Earnings per share (EPS) | -0.017 |
| Gross Margin | -9,861.29% |
| Net Profit Margin | -14,546.24% |
| Debt/Equity Ratio | 0% |
How did LIPI perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/02 04:59 |
| End of Day Share Price | 2025/01/02 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Lipidor AB (publ) is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|